This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
by Zacks Equity Research
Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Mylan's Generic Version of Advair Diskus Wins FDA Approval
by Zacks Equity Research
Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance
by Zacks Equity Research
Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.
Novartis Misses Earnings and Sales Estimates in Q4
by Zacks Equity Research
Novartis (NVS) missed estimates both for earnings and sales in the fourth quarter of 2018.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.
Alnylam & Medison Partner to Market RNAi Products in Israel
by Zacks Equity Research
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
by Zacks Equity Research
Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.
NVS or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. AZN: Which Stock Is the Better Value Option?
Intrexon Signs Licensing Agreement with Next Green Wave
by Zacks Equity Research
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off
by Zacks Equity Research
Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.
NASH Space in Focus in 2019 as Firms Look to Diversify
by Zacks Equity Research
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Novartis' Crizanlizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Tilray Gains More Than 200%: Is There More Scope for Growth?
by Zacks Equity Research
Tilray (TLRY) gains more than 200% in the past six months. Strategic deals should propel further growth.
Bristol-Myers' (BMY) Sprycel Gets FDA Nod for Label Expansion
by Zacks.com
Bristol-Myers' (BMY) obtains FDA approval for the label expansion of leukemia drug Sprycel to include pediatric population.
Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
by Zacks Equity Research
Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.